Alpha Cognition Inc (ACOG)vsAstraZeneca PLC (AZN)
ACOG
Alpha Cognition Inc
$5.82
-1.52%
HEALTHCARE · Cap: $138.05M
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 558207% more annual revenue ($60.44B vs $10.83M). AZN leads profitability with a 17.2% profit margin vs -234.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ACOG
Avoid28
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACOG.
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 20.7% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -43.8% — below average capital efficiency
Negative free cash flow — burning cash
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Price/Book, Revenue Growth. Revenue growth of 20.7% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ACOG
The primary concerns for ACOG are EPS Growth, Market Cap, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ACOG profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.39 — expect wider price swings.
ACOG is growing revenue faster at 20.7% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is a forward-thinking biopharmaceutical company dedicated to pioneering innovative therapies for neurodegenerative conditions, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, targets cognitive enhancement, addressing significant unmet needs within the aging demographic. By harnessing a proprietary neuroscience platform and robust research and development initiatives, Alpha Cognition is positioned to drive advancements in patient care. As the company advances its clinical pipeline and explores additional therapeutic avenues, it represents a compelling investment prospect for institutional investors seeking exposure to transformative innovations in the healthcare sector.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?